McDermott Advised Vivet Therapeutics on the Sale of its Equity to Pfizer

Overview


McDermott Will & Emery advised Vivet Therapeutics, a gene therapy biotechnology company dedicated to the development of hereditary liver disorders, in the acquisition by the American group Pfizer of a 15% equity interest in Vivet. The transaction included an exclusive option to acquire all outstanding shares. Pfizer and Vivet will collaborate in the development of VTX-801, Vivet’s proprietary treatment for Wilson disease.

According to the terms of the agreement, Pfizer paid approximately 45 million euros upon signature and could pay up to 560 million euros, including the payment of the exercise of the option, subject to the completion of certain clinical, regulatory and commercial milestones. Pfizer may exercise its option to acquire 100% of Vivet following the company’s delivery of certain data from the Phase I/II clinical trial for VTX-801.

McDermott Will & Emery advised Vivet Therapeutics with a team composed of Emmanuelle Trombe and Anthony Paronneau, Partners, Mathilde Peschard, Stephan de Groër on corporate aspects, and Partner Antoine Vergnat, and Côme de Saint-Vincent on the tax aspects.

About McDermott


McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With 20 locations on three continents, our team works seamlessly across practices, industries and geographies to deliver highly effective—and often unexpected—solutions that propel success. More than 1,100 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

Media Contacts